Influence of tetrachlorodecaoxide (Ryoxon) on the development of leukemia after total-body gamma-irradiation.
The effect of tetrachlorodecaoxide (TCDO) treatment after total-body irradiation (TBI) with gamma-rays (single dose, about LD 50) on the development of radiation-induced leukemia was tested in rats. TCDO was applied intravenously from day 4 through day 11. The control group was exposed to the same dosage of X-rays (TBI), but received physiological saline solution instead of TCDO. Compared to the control group, TCDO therapy initially markedly increased the survival rate: 72 versus 44% (6 months after TBI) and 36 versus 20% (1-year survival rate). The overall survival, however, was not significantly prolonged. TBI caused leukemia in 36% of the rats in the irradiation control group without TCDO treatment, however, none of 24 rats treated with TCDO after X-ray exposure developed leukemia. Since in this study TCDO was only administered for 8 days during the acute phase of radiation syndrome, we suppose that additional TCDO treatment at various times later on would lead to even better results.
Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg.
S R
SR
Kempf
K
K
Blaszkiewitz
R E
RE
Port
S
S
Ivankovic
D000818:Animals; D002713:Chlorine / Q000627:therapeutic use*; D005720:Gamma Rays; D007953:Leukemia, Radiation-Induced / Q000517:prevention & control*; D008297:Male; D010087:Oxides / Q000627:therapeutic use*; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D051381:Rats; D014916:Whole-Body Irradiation / Q000009:adverse effects*
D010087:Oxides; D011837:Radiation-Protective Agents; D002713:Chlorine; C041955:tetrachlorodecaoxide